Neupedix (Alprostadil)

Alprostadil mimics natural prostaglandin E1, binding to specific receptors on vascular smooth muscle. This activates adenylate cyclase, raises intracellular cAMP levels, and causes smooth‑muscle relaxation. The resulting vasodilation improves blood flow and inhibits platelet aggregation, which underlies its therapeutic effects.

The dosage of Neupedix is determined by the prescribing clinician based on the indication, patient characteristics, and clinical response. Healthcare professionals set the appropriate amount, concentration, and infusion rate for each individual case.

Safety of alprostadil in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Neupedix (alprostadil) is a prostaglandin‑based vasodilator administered intravenously, whereas many alternatives such as phosphodiesterase‑5 inhibitors (e.g., sildenafil) are oral agents. Alprostadil provides a rapid, localized effect but requires professional administration, while oral agents are self‑administered but may have different side‑effect profiles.

Neupedix should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Neupedix is supplied for intravenous use. It is typically administered by a qualified healthcare professional under aseptic conditions, either as a slow infusion or direct injection, depending on the clinical protocol and indication.

Serious risks include severe hypotension, priapism (prolonged erection), allergic reactions such as anaphylaxis, myocardial infarction, and pulmonary edema. Patients should be monitored closely for these events, and treatment should be stopped immediately if they occur.

Neupedix is contraindicated in patients with known hypersensitivity to alprostadil or other prostaglandin E1 analogs, those with uncontrolled hypertension, recent myocardial infarction, or severe cardiovascular disease where additional vasodilation could be harmful.